TY - JOUR
T1 - Seroprotection against tetanus in the Italian general population
AU - Sero-epidemiological Study Group
AU - Bagordo, Francesco
AU - Grassi, Tiziana
AU - Rota, Maria Cristina
AU - Castiglia, Paolo
AU - Baldovin, Tatjana
AU - Della Polla, Giorgia
AU - Panico, Alessandra
AU - Ogliastro, Matilde
AU - Marchi, Serena
AU - Vicentini, Costanza
AU - Immordino, Palmira
AU - Savio, Marta
AU - Gabutti, Giovanni
N1 - nicht zu werten, lediglich study group member; Microbiology and Virology Laboratory, Health District of Bolzano, Alto Adige Health Authority, Italy
PY - 2024/7/25
Y1 - 2024/7/25
N2 - BACKGROUND: Tetanus is a non-communicable disease, preventable with vaccination. Despite the implemented vaccination strategy, a certain number of tetanus cases per year continue to occur. The aim of the study was to evaluate the seroprevalence of anti-tetanus antibodies in the Italian population by age, sex and geographical area.METHODS: To determine the level of tetanus-specific antibodies, an immunoenzymatic assay was used.RESULTS: A total of 3,821 serum samples were collected in the years 2019-20 from healthy subjects aged 6-90 years residing in 13 Italian regions. Overall, 85 % of the tested subjects resulted positive. The rate of subjects protected against tetanus showed a gradual decrease from the younger age groups to the older ones (6-12 years: 93.6 %, 13-24 years: 91.8 %, 25-39 years: 91.0 %, 40-64 years: 78.2 %, ≥ 65 years: 45.3 %); this is particularly evident in the Southern regions and Islands. Moreover, the prevalence of subjects with low protection (<0.1 IU/ml) was significantly higher in the ≥ 65 age group (10.3 %). Males and females' prevalence showed a significant difference only in the oldest age group (M: 60.8 %, F: 30.4 %). In general, a higher prevalence was observed for Northern (90.8 %) and Central regions (87.3 %) than Southern regions and Islands (80.0 %).CONCLUSION: These data, compared with epidemiological ones which showed a high number of cases in the elderly, confirmed that the population with lower protection has a greater risk of contracting the disease, demonstrating the need for adequate immunization through both primary vaccination and boosters for all ages and both sexes, in order to provide lifelong protection.
AB - BACKGROUND: Tetanus is a non-communicable disease, preventable with vaccination. Despite the implemented vaccination strategy, a certain number of tetanus cases per year continue to occur. The aim of the study was to evaluate the seroprevalence of anti-tetanus antibodies in the Italian population by age, sex and geographical area.METHODS: To determine the level of tetanus-specific antibodies, an immunoenzymatic assay was used.RESULTS: A total of 3,821 serum samples were collected in the years 2019-20 from healthy subjects aged 6-90 years residing in 13 Italian regions. Overall, 85 % of the tested subjects resulted positive. The rate of subjects protected against tetanus showed a gradual decrease from the younger age groups to the older ones (6-12 years: 93.6 %, 13-24 years: 91.8 %, 25-39 years: 91.0 %, 40-64 years: 78.2 %, ≥ 65 years: 45.3 %); this is particularly evident in the Southern regions and Islands. Moreover, the prevalence of subjects with low protection (<0.1 IU/ml) was significantly higher in the ≥ 65 age group (10.3 %). Males and females' prevalence showed a significant difference only in the oldest age group (M: 60.8 %, F: 30.4 %). In general, a higher prevalence was observed for Northern (90.8 %) and Central regions (87.3 %) than Southern regions and Islands (80.0 %).CONCLUSION: These data, compared with epidemiological ones which showed a high number of cases in the elderly, confirmed that the population with lower protection has a greater risk of contracting the disease, demonstrating the need for adequate immunization through both primary vaccination and boosters for all ages and both sexes, in order to provide lifelong protection.
KW - Humans
KW - Middle Aged
KW - Female
KW - Italy/epidemiology
KW - Male
KW - Adult
KW - Adolescent
KW - Aged
KW - Tetanus/prevention & control
KW - Child
KW - Young Adult
KW - Seroepidemiologic Studies
KW - Aged, 80 and over
KW - Antibodies, Bacterial/blood
KW - Tetanus Toxoid/immunology
KW - Vaccination/statistics & numerical data
KW - Prevalence
U2 - 10.1016/j.vaccine.2024.05.015
DO - 10.1016/j.vaccine.2024.05.015
M3 - Original Article
C2 - 38762356
SN - 0264-410X
VL - 42
SP - 4040
EP - 4045
JO - VACCINE
JF - VACCINE
IS - 19
ER -